I'm happy to try to answer that question, at least as a starting point.
We have in Canada a pan-Canadian health technology assessment agency called CADTH, Canadian Agency for Drugs and Technologies in Health. I think their CEO has either already testified or will soon be testifying.
They rely on well-established scientific methods to review the clinical evidence and to conduct what we call cost-effectiveness analyses or value-for-money analyses. Obviously, these kinds of analyses take a lot of resources and take time. They can be conducted in ways that are better, and in ways that are quick and dirty, if you will.
Supporting the kinds of agencies that do this work is important. Katherine mentioned that we have significant capacity in Canada to do this work, and I would agree with her assessment. We've probably been leaders in economic evaluation for several decades, along with the British and the Australians and those in a few other countries.
Arguably, organizations like CADTH would need more resources to do this work if there were to be a national formulary or a national pharmacare plan.